BG62951B1 - Фармацевтични форми на невроклетъчен растежен фактор - Google Patents

Фармацевтични форми на невроклетъчен растежен фактор Download PDF

Info

Publication number: BG62951B1
Authority: BG; Bulgaria
Prior art keywords: ngf; aqueous; forms; neurocellular; buffer
Prior art date: 1993-08-20

Application number

BG100371A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG100371A (bg

Inventor

Victoria Knepp

Deborah Lidgate

Richard Maskiewicz

Leo Gu

Original Assignee

Syntex (U.S.A.) Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-20

Filing date

1996-02-19

Publication date

2000-12-29

1996-02-19 Application filed by Syntex (U.S.A.) Inc. filed Critical Syntex (U.S.A.) Inc.

1996-12-31 Publication of BG100371A publication Critical patent/BG100371A/bg

2000-12-29 Publication of BG62951B1 publication Critical patent/BG62951B1/bg

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
239000003102 growth factor Substances 0.000 title claims description 19
238000004108 freeze drying Methods 0.000 claims abstract description 39
239000000203 mixture Substances 0.000 claims abstract description 36
239000000872 buffer Substances 0.000 claims abstract description 33
238000009472 formulation Methods 0.000 claims abstract description 28
108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 21
102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 21
235000000346 sugar Nutrition 0.000 claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
229930006000 Sucrose Natural products 0.000 claims description 11
239000000945 filler Substances 0.000 claims description 11
239000005720 sucrose Substances 0.000 claims description 11
239000011780 sodium chloride Substances 0.000 claims description 10
238000001802 infusion Methods 0.000 claims description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
229930195725 Mannitol Natural products 0.000 claims description 8
239000000594 mannitol Substances 0.000 claims description 8
235000010355 mannitol Nutrition 0.000 claims description 8
241000282412 Homo Species 0.000 claims description 3
238000000185 intracerebroventricular administration Methods 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 2
102000015336 Nerve Growth Factor Human genes 0.000 abstract description 134
108010025020 Nerve Growth Factor Proteins 0.000 abstract description 133
150000008163 sugars Chemical class 0.000 abstract description 10
239000000644 isotonic solution Substances 0.000 abstract description 2
229940053128 nerve growth factor Drugs 0.000 abstract 3
230000001537 neural effect Effects 0.000 abstract 1
238000004007 reversed phase HPLC Methods 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 21
230000000694 effects Effects 0.000 description 15
238000012360 testing method Methods 0.000 description 15
238000000034 method Methods 0.000 description 14
239000000243 solution Substances 0.000 description 12
230000004071 biological effect Effects 0.000 description 11
238000003860 storage Methods 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
-1 many other proteins Chemical compound 0.000 description 9
238000011084 recovery Methods 0.000 description 9
239000012472 biological sample Substances 0.000 description 8
239000011521 glass Substances 0.000 description 8
239000002609 medium Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
239000000523 sample Substances 0.000 description 6
238000001179 sorption measurement Methods 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
238000007710 freezing Methods 0.000 description 5
230000008014 freezing Effects 0.000 description 5
210000002569 neuron Anatomy 0.000 description 5
229920000573 polyethylene Polymers 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000000969 carrier Substances 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
230000007774 longterm Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
230000008859 change Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000005496 eutectics Effects 0.000 description 3
239000007943 implant Substances 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000011148 porous material Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
101710179738 6,7-dimethyl-8-ribityllumazine synthase 1 Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 2
101710186608 Lipoyl synthase 1 Proteins 0.000 description 2
101710137584 Lipoyl synthase 1, chloroplastic Proteins 0.000 description 2
101710090391 Lipoyl synthase 1, mitochondrial Proteins 0.000 description 2
108091008604 NGF receptors Proteins 0.000 description 2
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
230000030833 cell death Effects 0.000 description 2
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
210000002932 cholinergic neuron Anatomy 0.000 description 2
230000001886 ciliary effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000002840 non-reducing disaccharides Chemical class 0.000 description 1
230000009972 noncorrosive effect Effects 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BG100371A 1993-08-20 1996-02-19 Фармацевтични форми на невроклетъчен растежен фактор BG62951B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/109,798 US6277828B1 (en)	1993-08-20	1993-08-20	Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en)	1993-08-20	1994-08-16	Pharmaceutical formulations of nerve growth factor

Publications (2)

Publication Number	Publication Date
BG100371A BG100371A (bg)	1996-12-31
BG62951B1 true BG62951B1 (bg)	2000-12-29

Family

ID=22329623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG100371A BG62951B1 (bg)	1993-08-20	1996-02-19	Фармацевтични форми на невроклетъчен растежен фактор

Country Status (31)

Country	Link
US (2)	US6277828B1 (pt)
EP (1)	EP0721343B1 (pt)
JP (2)	JP4592830B2 (pt)
KR (1)	KR100341193B1 (pt)
CN (1)	CN1163265C (pt)
AT (1)	ATE226085T1 (pt)
AU (1)	AU677699B2 (pt)
BG (1)	BG62951B1 (pt)
BR (1)	BR9407278A (pt)
CA (1)	CA2169834C (pt)
CZ (1)	CZ292422B6 (pt)
DE (1)	DE69431562T2 (pt)
DK (1)	DK0721343T3 (pt)
ES (1)	ES2181723T3 (pt)
FI (1)	FI113241B (pt)
HU (1)	HU228152B1 (pt)
IL (3)	IL110725A (pt)
LT (1)	LT4051B (pt)
LV (1)	LV11279B (pt)
NO (1)	NO317627B1 (pt)
NZ (1)	NZ271873A (pt)
PL (1)	PL176387B1 (pt)
PT (1)	PT721343E (pt)
RO (1)	RO114742B1 (pt)
RU (1)	RU2126265C1 (pt)
SI (1)	SI9420048B (pt)
SK (1)	SK284064B6 (pt)
TW (1)	TW427905B (pt)
UA (1)	UA43348C2 (pt)
WO (1)	WO1995005845A1 (pt)
ZA (1)	ZA946333B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
EP0831883A1 (en) *	1995-05-12	1998-04-01	The Rockefeller University	Treatment of alzheimer disease by modulation of synapsins
EP0862452B1 (en) *	1995-11-07	2003-12-10	Genentech, Inc.	Stabilizing formulation for ngf
US6964947B1 (en) *	1995-11-07	2005-11-15	Genentech, Inc.	Stabilizing formulation for NGF
US6090781A (en) *	1996-11-06	2000-07-18	Genentech, Inc.	Stabilizing formulation for NGF
JP2000511059A (ja) *	1996-05-29	2000-08-29	ユニバーサルプリザーベーションテクノロジーズ，インコーポレイテッド	ガラス化による長期貯蔵保存
CN1059597C (zh) *	1996-08-08	2000-12-20	陈素兰	神经损伤修复制剂
DE69836543T2 (de) *	1997-05-01	2007-09-20	Protechtion Unlimited, Inc., Wilmington	Nervenwachstumsfaktor als impfstoffadjuvans
US6313089B1 (en)	1997-08-20	2001-11-06	Duke University	Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) *	1997-09-30	2001-10-16	デューク・ユニバーシティー	アポリポタンパク質ｅ／成長因子複合体およびその使用法
US6979442B1 (en)	1998-08-17	2005-12-27	Pfizer Inc.	Stabilized protein compositions
KR20040065278A (ko) *	2001-12-21	2004-07-21	노보 노르디스크 에이/에스	변경된 인자 ⅶ 폴리펩티드의 액체 조성물
PL370652A1 (en)	2001-12-21	2005-05-30	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
AR038568A1 (es) *	2002-02-20	2005-01-19	Hoffmann La Roche	Anticuerpos anti-a beta y su uso
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
DK2283856T3 (da)	2002-06-21	2017-11-20	Novo Nordisk Healthcare Ag	Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
AU2004222625A1 (en) *	2003-03-18	2004-09-30	Novo Nordisk Health Care Ag	Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) *	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
JP5627832B2 (ja) *	2003-05-23	2014-11-19	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	溶液中におけるタンパク質の安定化
CN1318087C (zh) *	2003-06-06	2007-05-30	北京三诺佳邑生物技术有限责任公司	去白蛋白神经生长因子制剂
WO2004112828A1 (en) *	2003-06-25	2004-12-29	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
ES2335994T3 (es) *	2003-07-01	2010-04-07	Novo Nordisk Health Care Ag	Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
ES2574581T3 (es)	2003-08-14	2016-06-20	Novo Nordisk Health Care Ag	Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
DE10355251A1 (de) *	2003-11-26	2005-06-23	Merck Patent Gmbh	Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
AU2004298789A1 (en) *	2003-12-19	2005-06-30	Novo Nordisk Health Care Ag	Stabilised compositions of factor VII polypeptides
US8017151B2 (en) *	2004-09-07	2011-09-13	Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center	Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en)	2004-09-07	2012-05-01	Board Of Regents Of The University Of Nebraska	Amphiphilic polymer-protein conjugates and methods of use thereof
US20090325978A1 (en) *	2006-08-14	2009-12-31	Katsumi Onai	Stable lyophilized preparation
JP4111995B1 (ja) *	2006-11-08	2008-07-02	株式会社メディカル・アプライアンス	神経栄養因子産生促進装置
EP1958618A1 (de)	2007-02-15	2008-08-20	Octapharma AG	Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
AU2009295590A1 (en) *	2008-09-26	2010-04-01	Adocia	Complex consisting of polysaccharide and an HBP
CN102232932B (zh) *	2010-04-27	2013-06-05	重庆莱美药业股份有限公司	果胶-阿霉素轭合物的冻干制剂及制备方法
ES2644824T3 (es)	2011-04-07	2017-11-30	Neovacs	Método para tratar afecciones relacionadas con IFNalfa
EP2812019A1 (en) *	2012-02-08	2014-12-17	Institut National De La Recherche Agronomique	Use of beta-nerve growth factor for inducing ovulation in mammals
EP3287140B1 (en) *	2015-04-21	2021-06-02	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Nerve growth factor composition and powder injection
WO2016169453A1 (zh) *	2015-04-21	2016-10-27	舒泰神（北京）生物制药股份有限公司	神经生长因子组合物及注射粉剂
WO2016169455A1 (zh) *	2015-04-21	2016-10-27	舒泰神（北京）生物制药股份有限公司	神经生长因子组合物和注射粉剂
US9868828B2 (en) *	2015-06-23	2018-01-16	Amolifescience Co., Ltd.	Defined three-dimensional microenvironment for stem cell
CN108883177A (zh)	2016-03-25	2018-11-23	安斯泰来制药株式会社	含有PEG化抗人NGF抗体Fab’片段的药物组合物
KR102783452B1 (ko)	2016-06-01	2025-03-19	세르비에 아이피 유케이 리미티드	폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
CN109260147B (zh) *	2018-10-15	2019-09-13	珠海亿胜生物制药有限公司	一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en)	2020-08-14	2023-09-26	Albcura Corporation	Albumin compositions and methods of producing and using same
IL302317A (en)	2020-10-28	2023-06-01	Dompe Farm Spa	Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4497431A1 (en) *	2023-07-27	2025-01-29	Dompé farmaceutici S.p.A.	Pharmaceutical formulation comprising nerve growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0193917A3 (en) *	1985-03-06	1987-09-23	American Cyanamid Company	Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
NZ235556A (en)	1986-11-05	1991-06-25	Ethicon Inc	Breast milk substitute containing recombinant human egf
NZ226170A (en) *	1987-09-18	1990-07-26	Ethicon Inc	Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) *	1988-03-18	1990-05-24	Fidia Farmaceutici	Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en)	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
JPH0418031A (ja) *	1989-02-16	1992-01-22	Hiroshi Saito	損傷治癒促進剤
US5169834A (en) *	1990-11-30	1992-12-08	American Cyanamid Company	Compositions and method for reducing vial breakage during lyophilization
AU1442592A (en) *	1991-02-20	1992-09-15	Nova Pharmaceutical Corporation	Controlled release microparticulate delivery system for proteins
JP3283288B2 (ja) *	1991-03-08	2002-05-20	電気化学工業株式会社	生理活性ペプチド製剤
JP2818834B2 (ja) *	1991-08-12	1998-10-30	大塚製薬株式会社	ＩＬ−１α安定化医薬製剤

1993
- 1993-08-20 US US08/109,798 patent/US6277828B1/en not_active Expired - Lifetime
1994
- 1994-08-16 EP EP94925903A patent/EP0721343B1/en not_active Expired - Lifetime
- 1994-08-16 CN CNB94193148XA patent/CN1163265C/zh not_active Expired - Lifetime
- 1994-08-16 CZ CZ1996424A patent/CZ292422B6/cs not_active IP Right Cessation
- 1994-08-16 PT PT94925903T patent/PT721343E/pt unknown
- 1994-08-16 ES ES94925903T patent/ES2181723T3/es not_active Expired - Lifetime
- 1994-08-16 AU AU75668/94A patent/AU677699B2/en not_active Expired
- 1994-08-16 JP JP50764495A patent/JP4592830B2/ja not_active Expired - Lifetime
- 1994-08-16 UA UA96020622A patent/UA43348C2/uk unknown
- 1994-08-16 SK SK183-96A patent/SK284064B6/sk not_active IP Right Cessation
- 1994-08-16 DK DK94925903T patent/DK0721343T3/da active
- 1994-08-16 AT AT94925903T patent/ATE226085T1/de active
- 1994-08-16 BR BR9407278A patent/BR9407278A/pt not_active Application Discontinuation
- 1994-08-16 DE DE69431562T patent/DE69431562T2/de not_active Expired - Lifetime
- 1994-08-16 PL PL94313084A patent/PL176387B1/pl unknown
- 1994-08-16 KR KR1020017005635A patent/KR100341193B1/ko not_active Expired - Lifetime
- 1994-08-16 RO RO96-00301A patent/RO114742B1/ro unknown
- 1994-08-16 HU HU9600371A patent/HU228152B1/hu unknown
- 1994-08-16 NZ NZ271873A patent/NZ271873A/en not_active IP Right Cessation
- 1994-08-16 RU RU96105951A patent/RU2126265C1/ru active
- 1994-08-16 WO PCT/US1994/009245 patent/WO1995005845A1/en not_active Ceased
- 1994-08-16 SI SI9420048A patent/SI9420048B/sl unknown
- 1994-08-16 CA CA002169834A patent/CA2169834C/en not_active Expired - Lifetime
- 1994-08-19 IL IL11072594A patent/IL110725A/en not_active IP Right Cessation
- 1994-08-19 ZA ZA946333A patent/ZA946333B/xx unknown
- 1994-08-19 IL IL124941A patent/IL124941A/en not_active IP Right Cessation
- 1994-08-30 TW TW083107604A patent/TW427905B/zh not_active IP Right Cessation
1996
- 1996-02-19 NO NO19960651A patent/NO317627B1/no not_active IP Right Cessation
- 1996-02-19 LV LVP-96-48A patent/LV11279B/en unknown
- 1996-02-19 BG BG100371A patent/BG62951B1/bg unknown
- 1996-02-19 LT LT96-011A patent/LT4051B/lt not_active IP Right Cessation
- 1996-02-19 FI FI960750A patent/FI113241B/fi not_active IP Right Cessation
1998
- 1998-06-16 IL IL12494198A patent/IL124941A0/xx active IP Right Grant
2001
- 2001-02-20 US US09/789,855 patent/US7074763B2/en not_active Expired - Fee Related
2007
- 2007-08-08 JP JP2007206876A patent/JP2007314572A/ja active Pending

Also Published As

Publication number	Publication date
ES2181723T3 (es)	2003-03-01
SI9420048B (sl)	2003-12-31
TW427905B (en)	2001-04-01
EP0721343A1 (en)	1996-07-17
CN1133012A (zh)	1996-10-09
US6277828B1 (en)	2001-08-21
LT96011A (en)	1996-07-25
DK0721343T3 (da)	2003-02-17
LT4051B (en)	1996-10-25
IL110725A0 (en)	1994-11-11
DE69431562T2 (de)	2003-06-18
HK1012990A1 (en)	1999-08-13
US7074763B2 (en)	2006-07-11
NZ271873A (en)	1996-10-28
NO960651D0 (no)	1996-02-19
SK284064B6 (sk)	2004-09-08
IL110725A (en)	2004-09-27
LV11279B (en)	1996-10-20
CN1163265C (zh)	2004-08-25
FI960750A0 (fi)	1996-02-19
SI9420048A (en)	1996-10-31
RU2126265C1 (ru)	1999-02-20
ZA946333B (en)	1996-02-19
IL124941A0 (en)	1999-01-26
NO960651L (no)	1996-02-19
BR9407278A (pt)	1996-10-01
IL124941A (en)	2006-12-10
AU677699B2 (en)	1997-05-01
LV11279A (lv)	1996-06-20
KR100341193B1 (ko)	2002-06-21
BG100371A (bg)	1996-12-31
HUT74728A (en)	1997-02-28
ATE226085T1 (de)	2002-11-15
EP0721343B1 (en)	2002-10-16
JP2007314572A (ja)	2007-12-06
AU7566894A (en)	1995-03-21
CA2169834A1 (en)	1995-03-02
JP4592830B2 (ja)	2010-12-08
PL176387B1 (pl)	1999-05-31
US20010007662A1 (en)	2001-07-12
HU9600371D0 (en)	1996-04-29
CA2169834C (en)	2008-11-04
FI113241B (fi)	2004-03-31
CZ42496A3 (en)	1996-05-15
CZ292422B6 (cs)	2003-09-17
RO114742B1 (ro)	1999-07-30
HU228152B1 (en)	2012-12-28
NO317627B1 (no)	2004-11-29
JPH10508000A (ja)	1998-08-04
PT721343E (pt)	2003-01-31
DE69431562D1 (de)	2002-11-21
WO1995005845A1 (en)	1995-03-02
PL313084A1 (en)	1996-05-27
UA43348C2 (uk)	2001-12-17
FI960750L (fi)	1996-02-20
SK18396A3 (en)	1996-10-02

Publication	Publication Date	Title
BG62951B1 (bg)	2000-12-29	Фармацевтични форми на невроклетъчен растежен фактор
US5981485A (en)	1999-11-09	Human growth hormone aqueous formulation
CA2139358C (en)	2001-02-13	Human growth hormone aqueous formulation
US6410511B2 (en)	2002-06-25	Formulations for amylin agonist peptides
US5763394A (en)	1998-06-09	Human growth hormone aqueous formulation
EP0448146B1 (en)	1994-06-15	Stabilized gonadotropin containing preparations
HK1002494B (en)	1998-08-28	Stabilized gonadotropin containing preparations
US5270057A (en)	1993-12-14	Stabilized gonadotropin containing preparations
KR100310796B1 (ko)	2002-06-24	신경생육인자약학배합물
HK1012990B (en)	2003-03-28	Pharmaceutical formulations of nerve growth factor
WO1995022342A1 (en)	1995-08-24	Pharmaceutical formulations of ciliary neurotrophic factor